CN107114787B - 一种阻止热量吸收的组合物 - Google Patents
一种阻止热量吸收的组合物 Download PDFInfo
- Publication number
- CN107114787B CN107114787B CN201710321480.5A CN201710321480A CN107114787B CN 107114787 B CN107114787 B CN 107114787B CN 201710321480 A CN201710321480 A CN 201710321480A CN 107114787 B CN107114787 B CN 107114787B
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- parts
- heat absorption
- kidney bean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 139
- 240000000249 Morus alba Species 0.000 claims abstract description 47
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 47
- 241000219357 Cactaceae Species 0.000 claims abstract description 46
- 229940054810 white kidney bean extract Drugs 0.000 claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 244000061456 Solanum tuberosum Species 0.000 claims description 26
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 26
- 240000002853 Nelumbo nucifera Species 0.000 claims description 21
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 21
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical group OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 150000008130 triterpenoid saponins Chemical group 0.000 claims description 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 2
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 claims description 2
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 claims description 2
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical group C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 claims description 2
- 239000012268 protein inhibitor Substances 0.000 claims description 2
- 229940121649 protein inhibitor Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 26
- 239000002994 raw material Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 description 52
- 102000004139 alpha-Amylases Human genes 0.000 description 19
- 108090000637 alpha-Amylases Proteins 0.000 description 19
- 229940024171 alpha-amylase Drugs 0.000 description 19
- 102000016679 alpha-Glucosidases Human genes 0.000 description 16
- 108010028144 alpha-Glucosidases Proteins 0.000 description 16
- 102000004882 Lipase Human genes 0.000 description 14
- 108090001060 Lipase Proteins 0.000 description 14
- 239000004367 Lipase Substances 0.000 description 14
- 229940040461 lipase Drugs 0.000 description 14
- 235000019421 lipase Nutrition 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000003674 animal food additive Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 244000247812 Amorphophallus rivieri Species 0.000 description 5
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002752 Konjac Polymers 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 235000019482 Palm oil Nutrition 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000252 konjac Substances 0.000 description 5
- 235000010485 konjac Nutrition 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000002540 palm oil Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000003392 amylase inhibitor Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940018333 calcium pyruvate Drugs 0.000 description 1
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- LVZSQWIWCANHPF-UHFFFAOYSA-N p-nitrophenyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LVZSQWIWCANHPF-UHFFFAOYSA-N 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/115—Konjak; Konntaku
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/12—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops of potatoes
- A23L19/15—Unshaped dry products, e.g. powders, flakes, granules or agglomerates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种阻止热量吸收的组合物,包括如下重量份的组分:白芸豆提取物30‑60份、仙人掌提取物5‑15份、桑叶提取物5‑25份。本发明还公开了一种阻止热量吸收的组合物的制备方法。本发明组合物的制备方法简单,各组分间就不同的功能有着明显的交互作用,与单一原料相比,本发明组合物能够全方位、多靶点的阻止热量的吸收,并且能够以最小量达到较好的效果,具有良好的市场推广价值。
Description
技术领域
本发明属于减肥保健品技术领域。更具体地,涉及一种阻止热量吸收的组合物及其制备方法和应用。
背景技术
改革开放以来,随着人们生活水平发生翻天覆地的变化,人们的生活方式也发生了迅速的转变。高热量、高脂肪、高糖分的食物摄入越来越多以及体力活动的普遍下降,使肥胖率在我国居民中迅速上升。世界卫生组织的最新数据显示,18岁及以上成年人中有超过19亿人超重,其中6亿人肥胖。肥胖是一种由多因素引起的慢性代谢疾病,并与II型糖尿病、高血压、高脂血症、高尿酸血症、缺血性心脑疾患、癌症等多种疾病有明显关系。过度的肥胖给行走带来很多不便,科学研究表明内脏脂肪积聚可引起机体代谢的变化,导致免疫力下降、糖尿病的发生等;肥胖的患者多数血液粘稠,血脂偏高,血管内血流阻力增加而导致高血压、高血脂等症状;肥胖还会增加身体及心脏负担,造成冠状动脉供血不足,心脏缺氧,引起心肌劳累而诱发冠心病。
肥胖是19世纪以来物质生活不断丰富的特殊产物,是一种由食欲和能量代谢紊乱引起的一种疾病,其根本原因是热量摄入和能量消耗间的失衡。人体摄入的主要能量来源是淀粉和脂肪,淀粉在进入人体后会经过唾液淀粉酶、胰淀粉酶、麦芽糖酶及葡萄糖苷酶等酶的作用,最后会水解成葡萄糖被小肠粘膜吸收,当人体吸收的葡萄糖多于所消耗的葡萄糖时,剩余的葡萄糖会转变为脂肪,造成脂肪的堆积;同理脂肪进入人体后在胃酸和胰脂肪酶的作用下转换为甘油和脂肪酸,并且经过小肠粘膜被吸收,一部分甘油和脂肪酸会氧化分解最终代谢为二氧化碳和水,一部分则会积累在肝脏上形成肝糖原,当肝糖原过多时同样会转化成脂肪。
目前市场上主要流行的减肥产品分为西医产品和中医产品,其中西医减肥产品是以奥利司他为代表的化学药品,虽然在效果上有一定的作用,但是其极大的副作用困扰着广大的消费者;中医减肥产品有减肥茶类的产品,据称有减肥的功效,由于其功效成分含量极低所以效果甚微。在市面上的各类减肥产品中,大部分的西医减肥产品均有不同程度的副作用,而使用中医理念的减肥产品其减肥药理作用不明确,效果也不是很明显。
对现有专利的检索情况如下:
专利CN 105533077 A《一种减肥保健茶》中仅将几种草本原料进行搭配,对其具体搭配机理以及效果均未进行深入研究,如今大部分人群的能量来源还是碳水化合物,对此专利进一步分析发现其中具有抑制淀粉吸收的仅有桑叶,可能会导致淀粉被分解而增加体内热量,不管是从生理代谢过程还是使用量角度而言均可能使得控制体内热量摄入效果受限。
专利CN104664406 A《一种具有减肥功效且安全健康的食品》将荷叶提取物、白芸豆提取物与丙酮酸钙、酵素、芒果籽提取物、木瓜蛋白酶、藤黄果提取物、苦瓜提取物进行搭配,虽从抑制α-淀粉酶活性,以及促进脂肪分解与代谢的角度入手,但各原料间的作用关系未进行详细研究。
专利CN 103478738《一种具有减肥塑身及体重管理作用的组合物》将水溶性膳食纤维、白芸豆提取物、低聚糖粉、山楂果提取物进行搭配,仅达到抑制淀粉吸收以及助于肠道健康的目的,而对摄入的脂肪并未进行严格的控制。
为了解决上述问题,急需根据人体生活水平及代谢特点提供一种能有阻止热量吸收且没有副作用的产品。
发明内容
本发明的一个目的在于提供一种阻止热量吸收的组合物(Total ColorieBlocker,TCB);该组合物采用中西医结合理念,全方位、多靶点的对热量进入人体的整个代谢进行阻隔,以达到阻止热量的吸收的效果。
本发明的另一个目的在于提供一种阻止热量吸收的组合物的制备方法。
为达到上述目的,本发明采用下述技术方案:
一种阻止热量吸收的组合物,包括如下重量份的组分:白芸豆提取物30-60份、仙人掌提取物5-15份、桑叶提取物5-25份。
进一步,所述组合物还包括如下重量份的组分:马铃薯提取物1-20份。
本发明在白芸豆提取物、仙人掌提取物、桑叶提取物的基础上添加了马铃薯提取物、棕榈油和魔芋粉,通过比较三种组合物抑制α-淀粉酶能力、抑制α-葡萄糖苷酶能力、抑制脂肪酶能力,表明本发明在白芸豆提取物、仙人掌提取物、桑叶提取物的基础上添加马铃薯提取物,达到协同增效的作用,相比其他组合物,能够显著提高对于α-淀粉酶、α-葡萄糖苷酶、脂肪酶的抑制能力,能有效阻隔热量的吸收。
进一步,所述组合物还包括如下重量份的组分:荷叶提取物1-20份。
本发明中白芸豆提取物中的主要功效成分是菜豆蛋白;仙人掌提取物中的主要功效成分是三萜皂苷;桑叶提取物中的主要功效成分是1-脱氧野尻霉素;马铃薯提取物中的主要有效成分是一种蛋白抑制剂;荷叶提取物中的主要有效成分是荷叶碱;以上提取物可采用市售或者根据本领域常规技术加工制备得到。
本发明组合物通过各组分的协同倍增作用和多重防御机制协同作用来共同阻止热量的吸收,主要作用机理为:首先,该菜豆蛋白能够抑制α-淀粉酶的活性,阻止淀粉分解与吸收;其次,即使部分淀粉被酶解后,桑叶提取物抑制葡萄糖苷酶的活性,减少葡萄糖的生成,进而阻止其合成脂肪;再者,在脂肪类物质进入小肠后,仙人掌提取物中的三萜皂苷能调节脂肪酶的活性,阻止脂肪被分解吸收;若部分脂肪被分解,分解产物可被荷叶提取物在小肠表面形成的脂肪隔离膜所阻止吸收并有效地排出体外;除此之外,马铃薯提取物可加快并延长人体内胆囊收缩素的释放,而胆囊收缩素是一种强大的多肽,可以促使胃以及大脑两大器官发出饱腹感和满足感的信号,从而达到降低食欲的效果。
本发明还提供了一种上述组合物的制备方法,包括:按所述重量份称取各组分,混匀,即可。
进一步,本发明上述组合物根据本领域常规技术加入适当的辅料,可以加工制备成片剂、胶囊剂、注射剂等。
本发明上述组合物可应用于制备抑制α-淀粉酶、α-葡萄糖苷酶、脂肪酶的药物、食品或保健品上。
需要注意的是,本发明中将所述白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物、荷叶提取物分别替换为白芸豆粉、仙人掌粉、桑叶粉、马铃薯粉和荷叶粉也在本发明保护范围之内。
本发明的有益效果如下:
1、与单一原料相比,本发明的组合物能够全方位、多靶点的阻止热量的吸收,并且能够以最小量达到较好的效果。
2、本发明组合物具有明显的协同效果,具有良好的市场推广价值。
3、本发明组合物制备方法简单,所述组合物通过各组分的协同倍增作用和多重防御机制协同作用来共同阻止热量的吸收。
具体实施方式
为了更清楚地说明本发明,下面结合优选实施例对本发明做进一步的说明。本领域技术人员应当理解,下面所具体描述的内容是说明性的而非限制性的,不应以此限制本发明的保护范围。
实施例1一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物30g、仙人掌提取物5g、桑叶提取物5g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物在三维混料机内混合均匀,即得。
实施例2一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物在三维混料机内混合均匀,即得。
实施例3一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物45g、仙人掌提取物10g、桑叶提取物15g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物在三维混料机内混合均匀,即得。
实施例4一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物30g、仙人掌提取物5g、桑叶提取物5g、马铃薯提取物1g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物在三维混料机内混合均匀,即得。
实施例5一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g、马铃薯提取物20g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物在三维混料机内混合均匀,即得。
实施例6一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物45g、仙人掌提取物10g、桑叶提取物15g、马铃薯提取物10g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物在三维混料机内混合均匀,即得。
实施例7一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物30g、仙人掌提取物5g、桑叶提取物5g、荷叶提取物1g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、荷叶提取物在三维混料机内混合均匀,即得。
实施例8一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g、荷叶提取物20g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、荷叶提取物在三维混料机内混合均匀,即得。
实施例9一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物45g、仙人掌提取物10g、桑叶提取物15g、荷叶提取物10g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、荷叶提取物在三维混料机内混合均匀,即得。
实施例10一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物30g、仙人掌提取物5g、桑叶提取物5g、马铃薯提取物1g、荷叶提取物1g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物、荷叶提取物在三维混料机内混合均匀,即得。
实施例11一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g、马铃薯提取物20g、荷叶提取物20g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物、荷叶提取物在三维混料机内混合均匀,即得。
实施例12一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物45g、仙人掌提取物10g、桑叶提取物15g、马铃薯提取物10g、荷叶提取物10g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、马铃薯提取物、荷叶提取物在三维混料机内混合均匀,即得。
对比例1一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物25g、桑叶提取物35g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物在三维混料机内混合均匀,即得。
对比例2一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g、棕榈油20g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、棕榈油在三维混料机内混合均匀,即得。
对比例3一种阻止热量吸收的组合物
一种阻止热量吸收的组合物的制备方法,包括如下步骤:
1)称取如下重量的组分:白芸豆提取物60g、仙人掌提取物15g、桑叶提取物25g、魔芋粉20g;
2)将称好的白芸豆提取物、仙人掌提取物、桑叶提取物、魔芋粉在三维混料机内混合均匀,即得。
试验例1本发明组合物抑制α-淀粉酶能力、抑制α-葡萄糖苷酶能力、抑制脂肪酶能力的测定
对不同重量份间的白芸豆提取物,仙人掌提取物,桑叶提取物制得的组合物进行抑制α-淀粉酶能力、抑制α-葡萄糖苷酶能力、抑制脂肪酶能力指标的测定,各指标按照以下方法测定,结果见表1。
抑制α-淀粉酶实验
将1mL浓度为5mg/L的α-淀粉酶溶液和1mL浓度为1mg/ml组合物的水提物溶液进行混合;并在37℃水浴中加热10min,得第一混合液;向所述第一混合液加入2mL质量百分数为1%的可溶性淀粉水溶液,并在37℃水浴中加热10min,得第二混合液;向所述第二混合液中加入2mLDNS试剂,并在沸水浴中加热5min,水浴加热结束后迅速冷却,并稀释至适当的倍数,然后在540nm处测定稀释液的吸光值。
α-淀粉酶的活性直接用A540读数表示,α-淀粉酶的抑制活性用α-淀粉酶抑制率表示,α-淀粉酶抑制率可按下式计算:
α-淀粉酶抑制率(%)=(AE540-AI540)/AE540╳100%
AE540=对照组的吸光值
AI540=加入组合物后的吸光值
抑制α-葡萄糖苷酶实验:
将1mL磷酸缓冲液(pH=6.8)、1mL浓度为0.5U/ml的α-葡萄糖苷酶溶液和浓度为1mg/ml组合物的水提物溶液1mL进行混合;并在37℃水浴中加热10min,得第一混合液;向所述第一混合液加入1mL浓度为6mmol/L的4-硝基苯基-α-D-吡喃葡糖苷,并在37℃水浴中加热15min,得第二混合液;向所述第二混合液中加入4mL浓度为0.2mol/L碳酸钠溶液终止反应。各取200μL反应液于96板空中,然后在415nm处测定吸光值。
α-葡萄糖苷酶可按下式计算:
α-葡萄糖苷酶抑制率(%)=(AE415-AI415)/AE415╳100%
AE415=对照组的吸光值
AI415=加入组合物后的吸光值
抑制脂肪酶实验:
将2.7mL磷酸缓冲液(pH=8.0)和浓度为10mg/mL组合物的水提物溶液进行混合;并在37℃水浴中加热10min,得第一混合液;向所述第一混合液加入300μL浓度为4mmol/L的4-硝基苯基棕榈酸酯,继续在37℃水浴中加热10min,得第二混合液;将所述第二混合液进行沸水浴10min,使反应终止,然后在400nm处测定吸光值。
脂肪酶抑制率可按下式计算:
脂肪酶抑制率(%)=(AE400-AI400)/AE400╳100%
AE400=对照组的吸光值
AI400=加入组合物后的吸光值
表1各组合物抑制酶活结果
对上述结果经Design-Expert 8.0.6设计试验并分析后,发现组合物对α-淀粉酶抑制率影响最大的因素为白芸豆提取物的添加量,脂肪酶的抑制率影响最大的因素为仙人掌提取物的添加量,α-葡萄糖苷酶的抑制率影响最大的因素为桑叶提取物的添加量,且三种原料之间均存在一定的交互作用,由此可见三者之间对抑制α-淀粉酶、抑制α-葡萄糖苷酶、抑制脂肪酶三个方面均有协同增效的作用。
试验例2比较实施例2、5和对比例1-3组合物抑制α-淀粉酶能力、抑制α-葡萄糖苷酶能力、抑制脂肪酶能力
对实施例2、5和对比例1-3的组合物对抑制α-淀粉酶能力、抑制α-葡萄糖苷酶能力、抑制脂肪酶能力进行测定,具体测定方法同试验例1,结果见表2。
表2对比组的抑制酶能力结果
组合物 | 抑制α-淀粉酶能力(%) | 抑制α-葡萄糖苷酶能力(%) | 抑制脂肪酶能力(%) |
实施例2 | 73.49 | 58.61 | 65.87 |
实施例5 | 97.85 | 78.59 | 76.06 |
对比例1 | 87.41 | 62.59 | 65.17 |
对比例2 | 88.53 | 64.06 | 68.39 |
对比例3 | 87.92 | 63.58 | 68.02 |
从表2中可以看出,马铃薯提取物与白芸豆提取物、仙人掌提取物、桑叶提取物具有很好的协同作用,相比于棕榈油和魔芋粉与白芸豆提取物、仙人掌提取物、桑叶提取物制成的组合物,能显著抑制α-淀粉酶能力、α-葡萄糖苷酶和脂肪酶的活力。
试验例3本发明组合物减肥效果试验
本实验全体受试者均经过人体成分分析仪判定为肥胖且有迫切的减肥欲望人群,一共272人,男性136人,女性136人,年龄均在25-35之间,都是从事类似工作的白领人群。
272名受试者随机分为17组,每组16人,其中1组为阳性对照组,余下16组,分别对应实施例1-12和对比例1-4。对照组每次食用6g糊精,每天2次,餐前0.5h食用;实施例和对比例组每天食用3g对应的组合物和3g糊精,每天食用2次,餐前0.5h食用。连续服用3个月后,对受试者的体重变化、体脂比、腰臀比进行统计,结果见表3。
表3、各组合物评价试验结果
由以上数据可以看出实施例1-12、对比例1-3组与阳性对照组试验数据相比均具有降低体重、体脂比、腰臀比的功效。另外,从以上数据可以看出:将实施例5中马铃薯提取物替换为棕榈油和魔芋粉时,在降低体重、体脂比、腰臀比的效果要明显低于马铃薯提取物,说明白芸豆提取物、仙人掌提取物、桑叶提取物与马铃薯提取物间具有较好的协同作用,四者协同在一起能够全方位、多靶点的阻止热量的吸收,并且能够达到最好的效果。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定,对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,这里无法对所有的实施方式予以穷举,凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。
Claims (3)
1.一种阻止热量吸收的组合物,其特征在于,由如下重量份的组分制成:白芸豆提取物30-60份、仙人掌提取物5-15份、桑叶提取物5-25份、马铃薯提取物1-20份和荷叶提取物1-20份;其中,
所述白芸豆提取物中的主要功效成分是菜豆蛋白;仙人掌提取物中的主要功效成分是三萜皂苷;桑叶提取物中的主要功效成分是1-脱氧野尻霉素;马铃薯提取物中的主要有效成分是蛋白抑制剂;荷叶提取物中的主要有效成分是荷叶碱。
2.一种如权利要求1所述组合物的制备方法,其特征在于,包括:按重量份称取白芸豆提取物30-60份、仙人掌提取物5-15份、桑叶提取物5-25份、马铃薯提取物1-20份和荷叶提取物1-20份,混匀,即可。
3.权利要求1所述组合物在制备阻止热量吸收的药物、食品或保健品上的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710321480.5A CN107114787B (zh) | 2017-05-09 | 2017-05-09 | 一种阻止热量吸收的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710321480.5A CN107114787B (zh) | 2017-05-09 | 2017-05-09 | 一种阻止热量吸收的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107114787A CN107114787A (zh) | 2017-09-01 |
CN107114787B true CN107114787B (zh) | 2020-11-13 |
Family
ID=59727062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710321480.5A Active CN107114787B (zh) | 2017-05-09 | 2017-05-09 | 一种阻止热量吸收的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107114787B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108142927A (zh) * | 2017-12-25 | 2018-06-12 | 诺和生物技术(天津)有限公司 | 一种用于满足运动控制体重需求的组合物及其制备方法 |
CN108402463A (zh) * | 2018-03-15 | 2018-08-17 | 广东正当年生物科技有限公司 | 一种植物源减肥组合物及其制备方法 |
CN110226750A (zh) * | 2019-06-28 | 2019-09-13 | 明安旭(上海)健康科技有限公司 | 一种可有效分解摄入糖分的组合物及其制备方法 |
CN110710658A (zh) * | 2019-07-31 | 2020-01-21 | 水滴客科技(北京)有限公司 | 一种阻止热量吸收的组合物、其制备方法及应用 |
CN111529709A (zh) * | 2020-06-03 | 2020-08-14 | 北京易思腾翻译服务有限公司 | 一种可用于体重控制且可逆转动脉粥样硬化的组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103096738A (zh) * | 2010-05-14 | 2013-05-08 | Inq制药有限公司 | 用于降低膳食脂肪吸收的组合物 |
CN103445150A (zh) * | 2012-06-02 | 2013-12-18 | 黄文涛 | 一种身体内环境平衡组合剂 |
CN103961395A (zh) * | 2014-05-21 | 2014-08-06 | 吕健军 | 一种植物提取物组合物及其用于调控血糖的方法 |
CN105795468A (zh) * | 2016-01-08 | 2016-07-27 | 天津天狮生物发展有限公司 | 一种具有减肥功效的组合物 |
CN106038704A (zh) * | 2016-05-25 | 2016-10-26 | 吴敏浩 | 一种用于抑制食物消化吸收的组合物、制备方法及用途 |
-
2017
- 2017-05-09 CN CN201710321480.5A patent/CN107114787B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103096738A (zh) * | 2010-05-14 | 2013-05-08 | Inq制药有限公司 | 用于降低膳食脂肪吸收的组合物 |
CN103445150A (zh) * | 2012-06-02 | 2013-12-18 | 黄文涛 | 一种身体内环境平衡组合剂 |
CN103961395A (zh) * | 2014-05-21 | 2014-08-06 | 吕健军 | 一种植物提取物组合物及其用于调控血糖的方法 |
CN105795468A (zh) * | 2016-01-08 | 2016-07-27 | 天津天狮生物发展有限公司 | 一种具有减肥功效的组合物 |
CN106038704A (zh) * | 2016-05-25 | 2016-10-26 | 吴敏浩 | 一种用于抑制食物消化吸收的组合物、制备方法及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN107114787A (zh) | 2017-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107114787B (zh) | 一种阻止热量吸收的组合物 | |
US20140342042A1 (en) | Method of lowering glycemic index of foods | |
CN107242552A (zh) | 具有缓解体力疲劳及增强免疫力功能的保健食品组合物 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
JP6228250B2 (ja) | 多糖消化阻害剤 | |
CN109757727A (zh) | 适用于肠型ⅱ人群的餐后血糖调节与预防的膳食组合物 | |
CN106999595A (zh) | 包含戊糖和多酚化合物的组合物 | |
JP5421348B2 (ja) | ラクトバシルス属微生物で発酵させた菊芋発酵抽出物を有効成分として含む糖尿病の予防及び治療用薬学的組成物(CompositioncontainingextractofJerusalemartichokefermentedbyLactobacillussp.forpreventingandtreatingdiabetesmellitus) | |
CN102872062A (zh) | 一种治疗或预防肥胖症以及代谢综合症的药物组合物 | |
KR20050089127A (ko) | 혈압강하 작용 및 항당뇨병 작용의 양(兩) 작용에 유효한보건식품 및 약제 | |
KR20150015305A (ko) | 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
CN101015352A (zh) | 一种用于减肥和降血脂的海洋功能食品 | |
CN109700028A (zh) | 适用于肠型ⅰ人群的餐后血糖调节与预防的膳食组合物 | |
CN101411781A (zh) | 普洱茶在制备治疗或预防糖尿病的药中的应用 | |
WO2004014159A1 (en) | Method of lowering glycaemic index of foods | |
CN107712234A (zh) | 一种红曲精片压片糖果 | |
CN114532544A (zh) | 降糖、控糖的谷果植物肽固体饮料 | |
CN110710658A (zh) | 一种阻止热量吸收的组合物、其制备方法及应用 | |
CN102178718A (zh) | 一种用于治疗糖尿病和防治心脑血管疾病的制剂 | |
JP4783882B2 (ja) | 新規α−アミラーゼ阻害活性物質、その製造方法及びその用途 | |
KR100973087B1 (ko) | 농산부산물을 이용한 당뇨병 치유용 건강기능식품의 제조방법 및 그 조성물 | |
CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 | |
CN1726988A (zh) | 一种具有调节血糖、血脂作用的中药组合物及其制备方法 | |
KR20040097813A (ko) | 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물 | |
NL2027132B1 (en) | Use of a composition in preparing a product that inhibits α-glucosidase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |